MA32075B1 - Composes presentant une activite antagoniste de crth2 - Google Patents
Composes presentant une activite antagoniste de crth2Info
- Publication number
- MA32075B1 MA32075B1 MA33081A MA33081A MA32075B1 MA 32075 B1 MA32075 B1 MA 32075B1 MA 33081 A MA33081 A MA 33081A MA 33081 A MA33081 A MA 33081A MA 32075 B1 MA32075 B1 MA 32075B1
- Authority
- MA
- Morocco
- Prior art keywords
- heteroaryl
- aryl
- alkyl
- independently represent
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Transplantation (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
Abstract
L'invention porte sur des composés représentés par la formule générale (i), dans laquelle w représente chloro ou fluoro ; r1 représente phényle éventuellement substitué par un ou plusieurs substituants choisis parmi halo, -cn, alkyle en c1-c6, -sor3, -so2r3, -so2n(r2)2, -n(r2)2, -nr2c(o)r3, -co2r2, - conr2r3, -no2, -or2, -sr2, -o(ch2)por2, et -o(ch2)po(ch2)qor2, où les r2 représentent chacun indépendamment hydrogène, alkyle en c1-c6, cycloalkyle en c3-c8, aryle ou hétéroaryle ; les r3 représentent chacun indépendamment alkyle en c1-c6, cycloalkyle en c3-c8, aryle ou hétéroaryle ; p et q représentent chacun indépendamment un entier de 1 à 3 ; et sur leurs sels, hydrates, solvates, complexes ou promédicaments pharmaceutiquement acceptables, qui sont utiles dans des compositions administrables par voie orale pour le traitement de maladies allergiques, telles que l'asthme, la rhinite allergique et la dermatite atopique.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0800874A GB0800874D0 (en) | 2008-01-18 | 2008-01-18 | Compounds having CRTH2 antagonist activity |
GB0820526A GB0820526D0 (en) | 2008-11-10 | 2008-11-10 | Compounds having crth2 antagonist activity |
PCT/GB2009/000142 WO2009090414A1 (fr) | 2008-01-18 | 2009-01-19 | Composés présentant une activité antagoniste de crth2 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA32075B1 true MA32075B1 (fr) | 2011-02-01 |
Family
ID=40473418
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA33081A MA32075B1 (fr) | 2008-01-18 | 2010-08-13 | Composes presentant une activite antagoniste de crth2 |
Country Status (25)
Country | Link |
---|---|
US (1) | US20090186923A1 (fr) |
EP (1) | EP2250161B1 (fr) |
JP (2) | JP2011509988A (fr) |
KR (1) | KR101644170B1 (fr) |
CN (1) | CN101932571B (fr) |
AU (1) | AU2009204700B2 (fr) |
BR (1) | BRPI0906786B1 (fr) |
CA (1) | CA2712017C (fr) |
CY (1) | CY1114748T1 (fr) |
DK (1) | DK2250161T3 (fr) |
ES (1) | ES2442717T3 (fr) |
HK (1) | HK1145175A1 (fr) |
HR (1) | HRP20140045T1 (fr) |
IL (1) | IL206959A (fr) |
MA (1) | MA32075B1 (fr) |
MX (1) | MX2010007833A (fr) |
MY (1) | MY155133A (fr) |
NZ (1) | NZ587251A (fr) |
PL (1) | PL2250161T3 (fr) |
PT (1) | PT2250161E (fr) |
RS (1) | RS53142B (fr) |
RU (1) | RU2503672C2 (fr) |
SI (1) | SI2250161T1 (fr) |
WO (1) | WO2009090414A1 (fr) |
ZA (1) | ZA201005799B (fr) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6962940B2 (en) | 2002-03-20 | 2005-11-08 | Celgene Corporation | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
GB0324763D0 (en) * | 2003-10-23 | 2003-11-26 | Oxagen Ltd | Use of compounds in therapy |
WO2009061676A2 (fr) * | 2007-11-06 | 2009-05-14 | Amira Pharmaceuticals, Inc. | Antagonistes de récepteurs pgd2 |
US20100298368A1 (en) * | 2007-11-06 | 2010-11-25 | Amira Pharmaceuticals, Inc. | Antagonists of pgd2 receptors |
US20110124683A1 (en) * | 2007-11-13 | 2011-05-26 | Oxagen Limited | Use of CRTH2 Antagonist Compounds |
WO2009090414A1 (fr) * | 2008-01-18 | 2009-07-23 | Oxagen Limited | Composés présentant une activité antagoniste de crth2 |
US7750027B2 (en) * | 2008-01-18 | 2010-07-06 | Oxagen Limited | Compounds having CRTH2 antagonist activity |
EP2240444A1 (fr) * | 2008-01-22 | 2010-10-20 | Oxagen Limited | Composés présentant une activité antagoniste de crth2 |
JP2011509990A (ja) * | 2008-01-22 | 2011-03-31 | オキサジェン リミテッド | Crth2アンタゴニスト活性を有する化合物 |
BRPI0907364A2 (pt) | 2008-02-01 | 2015-07-14 | Amira Pharmaceuticals Inc | Antagonistas aminoalquilbifenil n,n-disubstituídos de receptores d2 de prostaglandina |
JP2011512359A (ja) * | 2008-02-14 | 2011-04-21 | アミラ ファーマシューティカルズ,インク. | プロスタグランジンd2受容体のアンタゴニストとしての環式ジアリールエーテル化合物 |
US8497381B2 (en) | 2008-02-25 | 2013-07-30 | Panmira Pharmaceuticals, Llc | Antagonists of prostaglandin D2 receptors |
US8426449B2 (en) * | 2008-04-02 | 2013-04-23 | Panmira Pharmaceuticals, Llc | Aminoalkylphenyl antagonists of prostaglandin D2 receptors |
US20110112134A1 (en) * | 2008-05-16 | 2011-05-12 | Amira Pharmaceuticals, Inc. | Tricyclic Antagonists of Prostaglandin D2 Receptors |
WO2010008864A2 (fr) * | 2008-06-24 | 2010-01-21 | Amira Pharmaceuticals, Inc. | Antagonistes de cycloalcane[b]indole de récepteurs de prostaglandine d2 |
CN102076661B (zh) | 2008-07-03 | 2014-04-09 | 潘米拉制药公司 | 前列腺素d2受体的拮抗剂 |
GB2463788B (en) * | 2008-09-29 | 2010-12-15 | Amira Pharmaceuticals Inc | Heteroaryl antagonists of prostaglandin D2 receptors |
US8378107B2 (en) | 2008-10-01 | 2013-02-19 | Panmira Pharmaceuticals, Llc | Heteroaryl antagonists of prostaglandin D2 receptors |
WO2010042652A2 (fr) | 2008-10-08 | 2010-04-15 | Amira Pharmaceuticals, Inc. | Antagonistes hétéroalkyl biphényle des récepteurs de la prostaglandine d2 |
GB2465062B (en) * | 2008-11-06 | 2011-04-13 | Amira Pharmaceuticals Inc | Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors |
US8383654B2 (en) | 2008-11-17 | 2013-02-26 | Panmira Pharmaceuticals, Llc | Heterocyclic antagonists of prostaglandin D2 receptors |
EP2461809A4 (fr) * | 2009-07-31 | 2013-06-19 | Panmira Pharmaceuticals Llc | Compositions pharmaceutiques ophtalmiques d'antagonsites du récepteur dp2 |
SG10201404662YA (en) * | 2009-08-05 | 2014-10-30 | Panmira Pharmaceuticals Llc | Dp2 antagonist and uses thereof |
KR20120115989A (ko) | 2010-01-06 | 2012-10-19 | 판미라 파마슈티칼스, 엘엘씨 | Dp2 길항제 및 이의 용도 |
KR101444572B1 (ko) | 2010-03-22 | 2014-09-24 | 액테리온 파마슈티칼 리미티드 | 3-(헤테로아릴-아미노)-1,2,3,4-테트라히드로-9h-카르바졸 유도체 및 이의 프로스타글란딘 d2 수용체 조절제로서의 용도 |
GB201103837D0 (en) | 2011-03-07 | 2011-04-20 | Oxagen Ltd | Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid |
ES2596581T3 (es) | 2011-04-14 | 2017-01-10 | Actelion Pharmaceuticals Ltd. | Derivados de ácido 7-(heteroaril-amino)-6,7,8,9-tetrahidropirido[1,2-a]indol acético y su uso como moduladores del receptor de prostaglandina D2 |
SI2781508T1 (sl) * | 2011-11-17 | 2019-03-29 | Kbp Biosciences Co., Ltd. | Zlite obročne spojine, ki vsebujejo dušik za uporabo kot antagonisti CRTH2 |
GB201121557D0 (en) | 2011-12-15 | 2012-01-25 | Oxagen Ltd | Process |
US20140328861A1 (en) * | 2011-12-16 | 2014-11-06 | Atopix Therapeutics Limited | Combination of CRTH2 Antagonist and a Proton Pump Inhibitor for the Treatment of Eosinophilic Esophagitis |
KR20150032329A (ko) * | 2012-07-10 | 2015-03-25 | 에프. 호프만-라 로슈 아게 | 호흡기 세포융합 바이러스 감염의 치료 및 예방을 위한 신규한 인다졸 |
WO2014088113A1 (fr) | 2012-12-04 | 2014-06-12 | Millennium Pharmaceuticals, Inc. | Procédé prophylactique ou thérapeutique destiné au syndrome de sjögren utilisant des inhibiteurs/antagonistes spécifiques du récepteur ccr9 |
CN105050624A (zh) * | 2013-03-14 | 2015-11-11 | 细胞基因公司 | 利用阿普斯特来治疗银屑病关节炎的方法 |
GB201322273D0 (en) * | 2013-12-17 | 2014-01-29 | Atopix Therapeutics Ltd | Process |
ES2900426T3 (es) * | 2013-12-31 | 2022-03-16 | Rapamycin Holdings Llc | Preparaciones orales y uso de nanopartículas de rapamicina |
MY179356A (en) | 2014-03-17 | 2020-11-05 | Idorsia Pharmaceuticals Ltd | Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators |
CA2938107A1 (fr) | 2014-03-18 | 2015-09-24 | Actelion Pharmaceuticals Ltd | Derives d'acide aza-indol-acetique et leur utilisation comme modulateurs des recepteurs de la prostaglandine d2 |
GB201407820D0 (en) * | 2014-05-02 | 2014-06-18 | Atopix Therapeutics Ltd | Polymorphic form |
GB201407807D0 (en) * | 2014-05-02 | 2014-06-18 | Atopix Therapeutics Ltd | Polymorphic form |
GB201407813D0 (en) * | 2014-05-02 | 2014-06-18 | Atopix Therapeutics Ltd | Polymorphic form |
JPWO2015190316A1 (ja) * | 2014-06-09 | 2017-04-20 | 住友化学株式会社 | ピリジン化合物の製造方法 |
WO2016025686A1 (fr) | 2014-08-15 | 2016-02-18 | Celgene Corporation | Dosage d'aprémilast pour le traitement de maladies améliorées par l'inhibition de pde4 |
TWI711616B (zh) | 2015-09-15 | 2020-12-01 | 瑞士商愛杜西亞製藥有限公司 | 結晶型式 |
KR20200037857A (ko) | 2017-08-14 | 2020-04-09 | 알러간, 인코포레이티드 | 3,4-이치환된 3-시클로부텐-1,2-디온 및 그의 용도 |
US20220098197A1 (en) * | 2019-01-10 | 2022-03-31 | Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd | Salts of heterocyclic compound and use thereof |
CN114796264A (zh) * | 2021-01-27 | 2022-07-29 | 北京北工大科技园有限公司 | 金络合物在制备治疗新型冠状病毒肺炎的药物中的应用 |
US20230234909A1 (en) * | 2020-06-12 | 2023-07-27 | Nucmito Pharmaceuticals Co. Ltd. | Indene compounds, pharmaceutical compositions thereof, and their therapeutic applications |
EP4337628A1 (fr) * | 2021-05-15 | 2024-03-20 | Nucmito Pharmaceuticals Company Limited | Composés indènes, compositions pharmaceutiques à base de ceux-ci et leurs applications thérapeutiques |
CN115192584A (zh) * | 2022-06-09 | 2022-10-18 | 南方科技大学 | 一种纳米药物及其制备方法和应用 |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3557142A (en) | 1968-02-20 | 1971-01-19 | Sterling Drug Inc | 4,5,6,7-tetrahydro-indole-lower-alkanoic acids and esters |
BE790679A (fr) | 1971-11-03 | 1973-04-27 | Ici Ltd | Derives de l'indole |
GB1407658A (en) | 1973-03-06 | 1975-09-24 | Ici Ltd | Process for the manufacture of indole derivatives |
GB1460348A (en) | 1974-02-04 | 1977-01-06 | Ici Ltd | Quinazoline derivativesa |
DK151884C (da) | 1979-03-07 | 1988-06-13 | Pfizer | Analogifremgangsmaade til fremstilling af 3-(1-imidazolylalkyl)indolderivater eller farmaceutisk acceptable syreadditionssalte deraf |
US4363912A (en) * | 1980-12-15 | 1982-12-14 | Pfizer Inc. | Indole thromboxane synthetase inhibitors |
GB8607294D0 (en) | 1985-04-17 | 1986-04-30 | Ici America Inc | Heterocyclic amide derivatives |
GB9122590D0 (en) | 1991-10-24 | 1991-12-04 | Lilly Industries Ltd | Pharmaceutical compounds |
US6040426A (en) | 1996-06-05 | 2000-03-21 | Bml, Inc. | Human Th2 specific protein |
US6916841B2 (en) | 1998-02-25 | 2005-07-12 | Genetics Institute, Llc | Inhibitors of phospholipase enzymes |
YU59600A (sh) | 1998-03-31 | 2002-12-10 | The Institute For Pharmaceutical Discovery Inc. | Supstituisane indolalkanoidske kiseline |
TNSN99224A1 (fr) | 1998-12-01 | 2005-11-10 | Inst For Pharm Discovery Inc | Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique |
GB9902461D0 (en) * | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
AU772121B2 (en) | 1999-08-23 | 2004-04-08 | Bml, Inc. | Method of identifying properties of substance to prostaglandin D receptors |
WO2001051849A1 (fr) | 2000-01-14 | 2001-07-19 | Koninklijke Philips Electronics N.V. | Dispositif d'affichage |
AU2001238718A1 (en) | 2000-03-02 | 2001-09-12 | The Institutes For Pharmaceutical Discovery, Llc | Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor |
JP2001247570A (ja) | 2000-03-08 | 2001-09-11 | Japan Tobacco Inc | インドール酢酸化合物及びその製造方法 |
US6878522B2 (en) | 2000-07-07 | 2005-04-12 | Baiyong Li | Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2 |
SE0200411D0 (sv) | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
SE0200356D0 (sv) | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
US7534897B2 (en) | 2002-05-16 | 2009-05-19 | Shionogi & Co., Ltd. | Indole arylsulfonaimide compounds exhibiting PGD 2 receptor antagonism |
WO2003097042A1 (fr) | 2002-05-16 | 2003-11-27 | Shionogi & Co., Ltd. | Antagoniste de recepteur de pdg2 |
SE0201635D0 (sv) | 2002-05-30 | 2002-05-30 | Astrazeneca Ab | Novel compounds |
TW200307542A (en) | 2002-05-30 | 2003-12-16 | Astrazeneca Ab | Novel compounds |
US7364647B2 (en) | 2002-07-17 | 2008-04-29 | Eksigent Technologies Llc | Laminated flow device |
SE0202241D0 (sv) | 2002-07-17 | 2002-07-17 | Astrazeneca Ab | Novel Compounds |
NZ541234A (en) | 2002-12-20 | 2008-06-30 | Amgen Inc | Asthma and allergic inflammation modulators |
JP4324418B2 (ja) | 2003-08-05 | 2009-09-02 | 株式会社日立国際電気 | 基板処理装置および半導体デバイスの製造方法 |
SE0302232D0 (sv) | 2003-08-18 | 2003-08-18 | Astrazeneca Ab | Novel Compounds |
US20070232681A1 (en) | 2003-10-14 | 2007-10-04 | Oxagen Limited | Compounds Having Crth2 Antagonist Activity |
GB0324763D0 (en) | 2003-10-23 | 2003-11-26 | Oxagen Ltd | Use of compounds in therapy |
EP1740171B1 (fr) | 2004-03-11 | 2010-06-09 | Actelion Pharmaceuticals Ltd. | Derives d'acide indol-1-yl-acetique |
CA2563707A1 (fr) * | 2004-04-20 | 2005-11-03 | Pfizer Inc. | Methode de traitement de la douleur neuropathique au moyen d'un antagoniste du recepteur crth2 |
CA2581338A1 (fr) | 2004-09-21 | 2006-03-30 | Athersys, Inc. | Acides indole acetiques antagonistes du recepteur crth2 et ses utilisations |
GB0504150D0 (en) | 2005-03-01 | 2005-04-06 | Oxagen Ltd | Microcrystalline material |
GB0505048D0 (en) | 2005-03-11 | 2005-04-20 | Oxagen Ltd | Compounds with PGD antagonist activity |
PL65781Y1 (pl) | 2005-08-16 | 2012-02-29 | Katarzyna Kawczyńska | Wkładka kosmetyczna |
DK2046740T3 (da) * | 2006-07-22 | 2012-08-20 | Oxagen Ltd | Forbindelser med CRTH2-antagonistisk virkning |
GB0722203D0 (en) * | 2007-11-13 | 2007-12-19 | Oxagen Ltd | Use of CRTH2 antagonist compounds |
PT2327693E (pt) * | 2007-12-14 | 2012-07-24 | Pulmagen Therapeutics Asthma Ltd | Indoles e sua utilização terapêutica |
WO2009090414A1 (fr) * | 2008-01-18 | 2009-07-23 | Oxagen Limited | Composés présentant une activité antagoniste de crth2 |
-
2009
- 2009-01-19 WO PCT/GB2009/000142 patent/WO2009090414A1/fr active Application Filing
- 2009-01-19 NZ NZ587251A patent/NZ587251A/en not_active IP Right Cessation
- 2009-01-19 KR KR1020107017661A patent/KR101644170B1/ko active IP Right Grant
- 2009-01-19 RS RS20140016A patent/RS53142B/en unknown
- 2009-01-19 DK DK09702598.5T patent/DK2250161T3/da active
- 2009-01-19 MY MYPI2010003390A patent/MY155133A/en unknown
- 2009-01-19 CN CN200980103456.8A patent/CN101932571B/zh not_active Expired - Fee Related
- 2009-01-19 JP JP2010542688A patent/JP2011509988A/ja active Pending
- 2009-01-19 PT PT97025985T patent/PT2250161E/pt unknown
- 2009-01-19 EP EP09702598.5A patent/EP2250161B1/fr active Active
- 2009-01-19 MX MX2010007833A patent/MX2010007833A/es active IP Right Grant
- 2009-01-19 AU AU2009204700A patent/AU2009204700B2/en not_active Ceased
- 2009-01-19 SI SI200930822T patent/SI2250161T1/sl unknown
- 2009-01-19 PL PL09702598T patent/PL2250161T3/pl unknown
- 2009-01-19 CA CA2712017A patent/CA2712017C/fr active Active
- 2009-01-19 RU RU2010129027/04A patent/RU2503672C2/ru active
- 2009-01-19 ES ES09702598.5T patent/ES2442717T3/es active Active
- 2009-01-19 BR BRPI0906786-8A patent/BRPI0906786B1/pt not_active IP Right Cessation
- 2009-01-21 US US12/356,822 patent/US20090186923A1/en not_active Abandoned
-
2010
- 2010-07-12 IL IL206959A patent/IL206959A/en active IP Right Grant
- 2010-08-13 MA MA33081A patent/MA32075B1/fr unknown
- 2010-08-13 ZA ZA2010/05799A patent/ZA201005799B/en unknown
- 2010-12-14 HK HK10111663.1A patent/HK1145175A1/xx not_active IP Right Cessation
-
2014
- 2014-01-15 CY CY20141100031T patent/CY1114748T1/el unknown
- 2014-01-15 HR HRP20140045AT patent/HRP20140045T1/hr unknown
- 2014-05-07 JP JP2014095946A patent/JP5855162B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA32075B1 (fr) | Composes presentant une activite antagoniste de crth2 | |
PE20211203A1 (es) | Compuestos para el tratamiento de trastornos dependientes de cinasas | |
RS54260B1 (en) | AMINODIHYDROTIAZINE DERIVATIVES AS BACE INHIBITORS FOR ALZHEIMER DISEASE TREATMENT | |
RS53839B1 (en) | SPIROCYCLES AS INHIBITORS OF 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE 1 | |
ME01421B (me) | 5-supstituisani derivati kinazolinona kao protivtumorska sredstva | |
EA201101089A1 (ru) | Производные оксадиазола в качестве агонистов рецептора s1p1 | |
AR084976A1 (es) | Compuestos de bifenileno sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales | |
RS52605B (en) | Benzoic Acids (1-Phenyl-2-pyridin-4-yl) -ETHYL ESTERS AS PHOSPHODIESTERASE INHIBITORS | |
EA200970793A1 (ru) | Модуляторы рецепторов, активируемых пролифераторами пероксисом | |
RS53679B1 (en) | FURAZANOBENZIMIDAZOLES AS PROGRAMS FOR THE TREATMENT OF NEOPLASTIC OR AUTOIMMUNE DISEASES | |
MA33721B1 (fr) | Derives sulfonamides heterocycliques utilises comme inhibiteurs de mek | |
EA200701035A1 (ru) | Замещенные n-сульфониламинобензил-2-феноксиацетамидные соединения | |
TW200716527A (en) | Substituted aminoalkyl-and amidoalkyl-benzopyran derivatives | |
MA54386B1 (fr) | Modulateurs de trex1 | |
EA201000104A1 (ru) | Производные пиримидина, применимые для лечения воспалительных или аллергических патологических состояний | |
TW200607808A (en) | Pyrido-pyrimidine derivatives, preparation thereof and application thereof | |
EA201391537A1 (ru) | ЭТИНИЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ПОЛОЖИТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ mGluR5 | |
RS54595B1 (en) | 2-oxo-1-pyrrolidinyl imidazothiadiazole derivatives | |
MA32192B1 (fr) | Composés dérivés d'azétidines, leur préparation et leur application en thérapeutique | |
RU2012146325A (ru) | Терапевтическое средство или профилактическое средство для лечения фибромиалгии | |
HRP20041087B1 (hr) | Derivati n-acilaminobenzena kao selektivni inhibitori monoamin oksidaze b | |
CR11578A (es) | Derivados de oxadiazol activos e 1-fosfato de esfingosina | |
PL408251A1 (pl) | Skondensowane pochodne triazolu jako inhibitory fosfodiesterazy 10A | |
RS53965B1 (en) | ACILBENZENA DERIVATIVES | |
RS51504B (en) | FUNGICID COMPOSITIONS BASED ON PIRIDYL METHYLBENZAMIDE DERIVATIVES AND PROPAMOCARB |